Zelgen(SH:688266) Zheng Quan Ri Bao·2025-09-16 13:38Core Viewpoint - Zai Jiang Pharmaceutical has received feedback from the National Medical Products Administration (NMPA) regarding the conditional approval for the clinical trial of its injectable product ZG006, indicating progress in its development [2]. Group 1 - The company has received feedback from the Center for Drug Evaluation (CDE) of the NMPA regarding the conditional approval for the injectable ZG006 [2]. - Based on the current safety and efficacy data of ZG006 and the proposed target population, the CDE has agreed to allow the company to conduct key clinical trials for ZG006 [2]. - The company is actively advancing the key clinical trials for ZG006 in the specified indications and has recently completed the enrollment of the first subject [2].